Skip to main content

Gout & crystal arthropathies

Browse the latest news, expert commentary, and educational content on gout and crystal arthropathies.

06-12-2022 | Gout | News

CA72-4 independently associated with gout flare risk in people initiating ULT

Results from a prospective cohort study suggest that increased levels of serum CA72-4 at urate-lowering therapy initiation are an independent risk factor for recurrent gout flares.

29-11-2022 | Gout | News

The metabolic syndrome may influence the risk for gout

The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

06-10-2022 | Gout | News

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

SGLT2 inhibitors, a type of diabetes drug, are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

26-09-2022 | Risk prediction | News

Local environment impacts recurrent hospitalization risk in rheumatic disease

Individuals with rheumatic conditions living in areas with the highest social and heat vulnerability are significantly more likely to experience recurrent hospitalizations than those living in the least vulnerable areas, research suggests.

16-09-2022 | Gout | News

Gout risk factor prevalence may explain increased rates among Black Americans

The higher prevalence of gout among Black men and women than their White counterparts is related to diet, social determinants of health, and chronic kidney disease, indicates research published in JAMA Network Open.

Man with painful and swollen right foot due to gout inflammation (symbolic image with model)

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

15-07-2022 | Gout | News

Study highlights sex-specific CVD risks in men with gout

Regular allopurinol use and keeping serum urate levels within the target range may be associated with a reduced risk for cardiovascular events in men with gout and no history of cardiovascular disease, observational study findings indicate.

02-06-2022 | EULAR 2022 | Conference coverage | News

Topical alkalinizing treatment shows potential for acute gout

A transdermal alkalinizing and pain-relieving treatment has been shown to effectively reduce the pain intensity and duration of an acute gout flare in the phase 2 TARGET study.

02-06-2022 | EULAR 2022 | Conference coverage | News

Methotrexate add-on therapy boosts pegloticase efficacy in refractory gout

The addition of methotrexate to pegloticase for the treatment of uncontrolled gout improves the rate of sustained urate-lowering response over 6 months, show findings from the MIRROR randomized controlled trial.

05-05-2022 | Gout | News

Support for gout self-management for improving urate levels

Supported self-management improves attainment of urate targets in people with gout, research suggests.

04-05-2022 | COVID-19 | News

Colchicine prophylaxis associated with ‘markedly reduced’ gout flare risk after COVID-19 vaccination

COVID-19 vaccination with inactivated virus vaccines is associated with an increased risk for flares among men with gout, and colchicine prophylaxis may help reduce this risk, researchers report.

10-03-2022 | Gout | News

Colchicine use linked to reduced risk for CKD progression

Study findings published in Rheumatology show that long-term use of colchicine is associated with a decreased risk for adverse renal outcomes in people with hyperuricemia or chronic gout and stage G3–G4 chronic kidney disease.

07-03-2022 | COVID-19 | News

Gout linked to increased risk for COVID-19 diagnosis, mortality

People with gout, particularly women, may have an elevated risk for COVID-19 diagnosis and related death, suggest the results of a population-based study reported in The Lancet Rheumatology.

21-02-2022 | Cardiovascular disease | News

EULAR releases recommendations on CV risk management in RMD patients

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

Keep up with podcasts on this topic, available on